Anionic liposome formulation for oral delivery of thuricin CD, a potential antimicrobial peptide therapeutic

Simple item page
dc.contributor.funderScience Foundation Irelanden
dc.contributor.funderHORIZON EUROPE European Research Councilen
dc.date.accessioned2024-03-25T12:33:57Z
dc.date.available2024-03-25T12:33:57Z
dc.date.issued2024en
dc.description.abstractThuricin CD is a two-peptide antimicrobial produced by Bacillus thuringiensis. Unlike previous antibiotics, it has shown narrow spectrum activity against Clostridioides difficile, a bacterium capable of causing infectious disease in the colon. However, peptide antibiotics have stability, solubility, and permeability problems that can affect their performance in vivo. This work focuses on the bioactivity and bioavailability of thuricin CD with a view to developing a formulation for delivery of active thuricin CD peptides through the gastrointestinal tract (GIT) for local delivery in the colon. The results indicate that thuricin CD is active at low concentrations only when both peptides are present. While thuricin CD was degraded by proteases and was unstable and poorly soluble in gastric fluid, it showed increased solubility in intestinal fluid, probably due to micelle encapsulation. Based on this, thuricin CD was encapsulated in anionic liposomes, which showed increased activity compared to the free peptide, maintained activity after exposure to pepsin in gastric fluid and intestinal fluid, was stable in suspension for over 21 days at room temperature and for 60 days at 4 °C, and exhibited no toxicity to epithelial intestinal cells. These findings suggest that an anionic lipid-based nano formulation may be a promising approach for local oral delivery of thuricin CD.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.articleid123918en
dc.identifier.citationViera Herrera, C., O’Connor, P.M., Ratrey, P., Paul Ross, R., Hill, C. and Hudson, S.P. (2024) ‘Anionic liposome formulation for oral delivery of thuricin CD, a potential antimicrobial peptide therapeutic’, International Journal of Pharmaceutics, 654, 123918 (13pp). doi: 10.1016/j.ijpharm.2024.123918en
dc.identifier.doi10.1016/j.ijpharm.2024.123918en
dc.identifier.endpage13en
dc.identifier.issn0378-5173en
dc.identifier.journaltitleInternational Journal of Pharmaceuticsen
dc.identifier.startpage1en
dc.identifier.urihttps://hdl.handle.net/10468/15695
dc.identifier.volume654
dc.language.isoenen
dc.publisherElsevieren
dc.relation.projectinfo:eu-repo/grantAgreement/SFI/SFI Frontiers for the Future::Project/19/FFP/6485/IE/Modular Release of Dual Acting Antimicrobial Peptides (MORE-AMP)/en
dc.relation.projectinfo:eu-repo/grantAgreement/EC/HE::ERC::HORIZON-ERC/101054719/EU/Bacteriocins from interbacterial warfare as antibiotic alternative/BACtheWINNERen
dc.rights© 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectThuricin CDen
dc.subjectAntimicrobial peptidesen
dc.subjectBacteriocinsen
dc.subjectAntimicrobial resistanceen
dc.subjectLiposomesen
dc.titleAnionic liposome formulation for oral delivery of thuricin CD, a potential antimicrobial peptide therapeuticen
dc.typeArticle (peer-reviewed)en
Files
Original bundle
Now showing 1 - 2 of 2
Thumbnail Image
Name:
1-s2.0-S0378517324001522-main.pdf
Size:
7.51 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
Thumbnail Image
Name:
1-s2.0-S0378517324001522-mmc1.docx
Size:
556.41 KB
Format:
Microsoft Word XML
Description:
Supplementary data
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
APC Microbiome Ireland - Journal Articles
Microbiology - Journal Articles